ストックスクリーナーアプリを入手
0.00
100.00%
-0.2075
前日終値:
$0.2075
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$4.26M
収益：
$31.56M
当期純損益:
$-46.89M
株価収益率:
0.00
EPS:
-3.0329
ネットキャッシュフロー:
$-26.70M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$3.09
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Compare CASI vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
0.00 | 4.26M | 31.56M | -46.89M | -26.70M | -3.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 開始されました | Mizuho | Buy |
| 2020-10-23 | 開始されました | Oppenheimer | Outperform |
| 2016-09-22 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-23 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Casi Pharmaceuticals Inc (CASI) 最新ニュース
[Form 3] CASI Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CASI Pharmaceuticals (CASIF) CMO holds 116,333 fully vested options at $1.93 - Stock Titan
CASIF: CASI Pharmaceuticals Inc.Comparison to Industry - Zacks Investment Research
All News for CASIF : CASI Pharmaceuticals Inc. - Zacks Investment Research
CASI SEC FilingsCasi Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CASI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Wrap: Can CASI Pharmaceuticals Inc maintain its current growth rate2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Why Is CASI Pharmaceuticals, Inc. (CASIF) Stock Down Today? - Meyka
Aug Shorts: Whats the profit margin of CASI Pharmaceuticals IncPortfolio Value Report & Capital Efficient Trade Techniques - baoquankhu1.vn
Diluted net income available to common stockholders of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI (NASDAQ: CASI) director lists fully vested stock options on Form 3 - stocktitan.net
Director Alex Wu details CASI (CASIF) vested stock options and shares - Stock Titan
What is the current Price Target and Forecast for CASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research
Wei-Wu He and ETP funds update CASI Pharmaceuticals (CASI) 53% stake - Stock Titan
CASI Pharmaceuticals to be delisted from Nasdaq, shares to move to OTC market - MSN
CASI (NASDAQ: CASI) director He Wei-Wu details share and option stakes - Stock Titan
CASI Pharmaceuticals (CASI) director James Huang reports initial holdings - Stock Titan
What is the long term forecast for CASI Pharmaceuticals Inc stockEarnings Recap Report & Accurate Buy Signal Alerts - baoquankhu1.vn
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 - Quantisnow
CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022 - Quantisnow
Total assets of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Short Squeeze: Can CASI Pharmaceuticals Inc deliver consistent EPS growth2025 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? - Stocktwits
CASI Pharmaceuticals Inc. (CASIF) Price To Cash Flow - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Liabilities - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Return On Equity (TTM) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Long Term Debt (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Enterprise Value - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Expenses (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Book Value - Zacks Investment Research
CASI PHARMACEUTICALS INC (CASIF.US) Income Statements, Balance Sheet & Cashflow - Longbridge
CASI PHARMACEUTICALS INC (CASIF.US) Latest News & Headlines - Longbridge
CASI Pharmaceuticals, Inc.: Financial Data Forecasts Estimates and Expectations | CASIF | KYG1933S1012 - marketscreener.com
CASI Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | CASIF | KYG1933S1012 - marketscreener.com
CASI Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | CASIF | KYG1933S1012 - marketscreener.com
Casi Pharmaceuticals CEO David Cory to step down at end of March - Investing.com
CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role - TipRanks
Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits - Stock Titan
CASI Pharmaceuticals Inc. (CASIF) Debt Equity Ratio (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Price Book Value - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Cash From Operations (TTM) - Zacks Investment Research
CASIF (CASI Pharmaceuticals) PB Ratio : (As of Mar. 02, 2026) - GuruFocus
CASI Pharmaceuticals Inc. (CASIF) Return On Assets (TTM) - Zacks Investment Research
Net debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI Pharmaceuticals Inc. (CASIF) Earnings Yield (TTM) - Zacks Investment Research
EBIT per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
EBITDA per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
EBITDA margin % of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
After tax other income/expense of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Long term debt to total equity ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Casi Pharmaceuticals Inc (CASI) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):